Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ACADIA Pharmaceuticals Inc

3 Hidden Bargains in the Healthcare Sector

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer…

3 Specialty Pharma Stocks Addressing Unmet Medical Needs

3 Specialty Pharma Stocks Addressing Unmet Medical Needs

The specialty pharma sector is leading the charge in developing life-changing solutions for rare and chronic conditions. Amid this backdrop, investors might consider adding three fundamentally solid specialty pharma stocks, namely, Ipsen S.A. (IPSEY), ACADIA Pharmaceuticals (ACAD), and Neurocrine Biosciences (NBIX) in their portfolios. Read on….

3 Healthcare Stocks Analysts Expect to Rally Over 50%

3 Healthcare Stocks Analysts Expect to Rally Over 50%

With the growing demand for innovative healthcare services, increasing spending, and rising tech adoption, the healthcare market is booming. Amid this backdrop, investors could check out quality healthcare stocks ACADIA Pharmaceuticals (ACAD), Harvard Bioscience (HBIO), and LAVA Therapeutics (LVTX), which have significant upside potential. Continue reading.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

3 Pharma Stocks to Buy for Potential Financial Fortunes

Amid surging medicine demand and ongoing drug shortages, the pharmaceutical industry thrives, driving improved patient outcomes and promising growth opportunities for investors. So, it could be wise to invest in quality pharma stocks ACADIA Pharmaceuticals (ACAD), Neurocrine Biosciences (NBIX), and Supernus Pharmaceuticals (SUPN), which can help you fetch potential financial…

Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now

With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be…

3 Affordable Pharma Stocks to Buy for Portfolio Gains

The pharmaceutical market is anticipated to grow substantially in the upcoming years, owing to technological innovation and rising demand for personalized medicines. To that end, affordable pharma stocks ACADIA Pharmaceuticals (ACAD), Astellas Pharma (ALPMY), and Spero Therapeutics (SPRO), trading under $20, could be solid buys now. Read on….

inkl

Read news from The Economist, FT, and more,
with one subscription

4 Cutting-Edge Pharma Stocks for Portfolio Diversification

4 Cutting-Edge Pharma Stocks for Portfolio Diversification

The pharmaceutical industry is expected to grow rapidly due to increasing healthcare demand, technological advancements, and rising demand for innovative drugs. Therefore, for portfolio diversification, investors could consider buying fundamentally strong pharmaceutical stocks such as Bayer (BAYRY), Procaps Group (PROC), ACADIA Pharmaceuticals (ACAD), and Zoetis (ZTS). Read more.

Bolster Your Portfolio with These 3 Pharma Stock Buys

Bolster Your Portfolio with These 3 Pharma Stock Buys

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

3 Pharma Stocks to Buy for February Gains

3 Pharma Stocks to Buy for February Gains

The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs, a rapidly aging population, and the rise in chronic diseases. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Bausch Health Companies (BHC), and ACADIA…

3 Stocks Building up Major Momentum

3 Stocks Building up Major Momentum

Despite lingering macroeconomic headwinds, the broader market has shown remarkable fortitude this year and is poised for an even greater surge ahead. Hence, it could be wise to invest in fundamentally sound stocks Assurant (AIZ), ACADIA Pharmaceuticals (ACAD), and Accel Entertainment (ACEL), which have gained significant momentum lately. Continue reading….

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis

Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position. RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared…

Get all your
news in one place.

100's of premium titles.
One news app.

Why Acadia Pharma Shares Are Falling Today

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.

1

People

Kritika SarmahHer

Neha PanjwaniFrom

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

RBC Capital Markets

Mizuho Securities

Astellas Pharma Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

380,952 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play